A bioequivalence comparison of two formulations of rifampicin (300- vs 150-mg capsules): An open-label, randomized, two-treatment, two-way crossover study in healthy volunteers

Clinical Therapeutics

Volumn 32, Issue 10, 2010, Pages 1822-1831

  Chik, Zamri ^a   Basu, Roma Choudhury ^a   Pendek, Rokiah ^a   Lee, Toong Chow ^b   Mohamed, Zahurin ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b SCHOOL OF PHYSICS   (Malaysia)

Author keywords

Bioequivalence; HPLC; Pharmacokinetics; Rifampicin; Tuberculosis

Indexed keywords

25 DESACETYL RIFAMPICIN; DRUG METABOLITE; RIFAMPICIN; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BODY MASS; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG FORMULATION; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIBIOTICS, ANTITUBERCULAR; CAPSULES; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; RIFAMPIN; THERAPEUTIC EQUIVALENCY; YOUNG ADULT;

EID: 78650598044     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2010.09.006     Document Type: Article

References (20)

1. Petri WA Antimicrobial agents: Drugs used in the chemotherapy of tuberculosis, Mycobacterium avium complex disease and leprosy. Goodman & Oilman's the Pharmacological Basis ofTherapeutics 2001, 1273-1294. McGraw-Hill, New York, NY. 10th ed. J.G. Hardman, L.E. Limbird, A. Goodman Gilman (Eds.).
2. Chan ED, Iseman MD Current medical treatment for tuberculosis. BMJ. 2002, 325:1282-1286.
3. Peloquin CA, Namdar R, Singleton MD, Nix DE Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids [published correction appears in Chest. 1999;115:1485]. Chest. 1999, 115:12-18.
4. Rxlist.com.rifampin-clinical pharmacology, Accessed August 23, 2010. http://www.rxlist.com/rifadin-drug.htm.
5. Acocella G Clinical pharmacokinetics of rifampicin. Clin Pharmacokinet. 1978, 3:108-127.
6. Malaysian guideline for the conduct of bioavailability and bioequivalence studies 2000, Ministry of Health Malaysia, Accessed August 23, 2010. http://portal.bpfk.gov.my/index.cfm?menuid=51&parentid=50.
7. Guidance for Industry. Bioavailability and bioequivalence studies for orally administered drug products-general considerations 2003, US Dept of Health and Human Services (HHS), Food and Drug Administration (FDA)Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER)Center for Drug Evaluation and Research (CDER), Accessed August 23, 2010. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070124.pdf.
8. Note for guidance on the investigation of bioavailability and bioequivalence The European Agency for the Evaluation of Medicinal Products (EMEA), Committee for Proprietary Medicinal Products (CPMP)Committee for Proprietary Medicinal Products (CPMP), Accessed August 23, 2010. http://apps.who.int/prequal/info_applicants/BE/emea_bioequiv.pdf.
9. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice Accessed August 23, 2010. http://www.ikev.org/haber/stabilite/cd/14%201.13%20ICH%20M4%20CTD%20for%20CD.pdf.
10. Malaysian Guidelines for Good Clinical Practice 1999, Ministry of Health Malaysia, DTP Production, Kuala Lumpur, Malaysia.
11. Agrawal S, Singh I, Kaur KJ, et al. Bioequivalence trials of rifampicin containing formulations: Extrinsic and intrinsic factors in the absorption of rifampicin. Pharmacol Res. 2004, 50:317-327.
12. Guidance for Industry: Bioanalytical method validation 2001, US Dept of Health and Human Services (HHS), Food and Drug Administration (FDA)Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER)Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM)Center for Veterinary Medicine (CVM), Accessed August 23, 2010. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070107.pdf.
13. Gabrielson J, Weiner D Pharmacokinetic and Pharmacodynamic Data Analysis. Concept and Application 2006, Swedish Pharmaceutical Press, Stockholm, Sweden. 4th ed.
14. Shargel L, Yu A Applied Biopharmaceutics & Pharmacokinetics 1999, Appleton & Lange, Stamford, Conn. 4th ed.
15. Chik Z, Basu RC, Pendek R, et al. Comparative bioavailability study of two salbutamol tablets in healthy adult volunteers. Int J Pharmacol Ther. 2009, 47:413-418.
16. Agrawal S, Kaur KJ, Singh I, et al. Minimum sample size and sampling time requirements for assessment of rifampicin bioequivalence from FDC formulations. Int J Tuberc Lung Di's. 2005, 9:1273-1280.
17. Asean guidelines for the conduct of bioavailability and bioequivalence studies Accessed August 23, 2010. http://portal.bpfk.gov.my/index.cfm?menuid=51&parentid=50.
18. Steinijans VW, Diletti E Statistical analysis of bioavailability studies: Parametric and nonparametric con- fidence intervals. Eur J Clin Pharma- col. 1983, 24:127-136.
19. Schuirmann DJ A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987, 15:657-680.
20. Agrawal S, Kaur KJ, Singh I, et al. Assessment of bioequivalence of rifampicin, isoniazid and pyrazinamide in a four drug fixed dose combination with separate formulations at the same dose levels. Int J Pharm. 2002, 233:169-177.